TABLE 4

Multivariate analysis of the association of patient factors with efavirenz pharmacokinetic parameters in HIV-infected children with and without tuberculosis

PK parameteraPredictorEstimateSEStandardized estimateP value
CmaxAge (yrs)−0.0520.017−0.3460.004
Dose (mg)0.0030.0010.518<0.001
CYP2B6 516TT0.5760.0800.544<0.001
C12hAge (yrs)−0.0480.019−0.2790.014
Dose (mg)0.0030.0010.3660.001
CYP2B6 516TT0.7740.0880.637<0.001
CminAge (yrs)−0.0340.021−0.1770.121
Dose (mg)0.0020.0010.2800.015
CYP2B6 516TT0.8730.0980.652<0.001
AUC0–24hAge (yrs)−0.0590.024−0.2740.016
Dose (mg)0.0040.0010.403<0.001
CYP2B6 516TT0.9570.1090.630<0.001
CL/FAge (yrs)0.0420.0120.260<0.001
CYP2B6 516TT−0.7390.083−0.640<0.001
  • a Cmax, peak concentration; C12h, concentration at 12 h postdose; Cmin, minimum concentration; AUC0–24h, total area under the curve from time 0 to 24 h; CL/F, apparent oral clearance. TB coinfection status, sex, weight, and height were not associated with efavirenz pharmacokinetic parameters in the multivariate model.